Gerald L. Andriole, Jr., M.D. was most recently  Professor and Director of Urology at Johns Hopkins University in the National Capital Region, retiring in June 2023. Previously, he had been the Royce Distinguished Professor and Chief of Urologic Surgery at Washington University in St. Louis for over 20 years.

Dr. Andriole has significant expertise in prostate cancer screening, prevention and treatment. He was continuously funded by NIH from 1993-2021 and has contributed over 450 peer-reviewed publications (H-index of 112).   He chaired the Prostate Committee of NCI’s PLCO Cancer Screening Trial and led the international REDUCE Prostate Cancer Chemoprevention Trial.  He also chaired the Prostate Committee of the Society of Urologic Oncology Clinical Trials Consortium.

Dr. Andriole is an elected member of the American Surgical Association, American Association of Genitourinary Surgeons, and the Clinical Society of Genitourinary Surgeons.  He received the Outstanding Achievement Award from the Urologic Oncology Branch of NCI, the Distinguished Clinician Award from Washington University, the Distinguished Alumni Award from Jefferson Medical College and the Williams Award for Prostate Cancer Research Excellence from the American Urologic Association Urology Care Foundation.

Dr. Andriole participated in the 5-year accelerated medical program at Penn State University and Jefferson Medical College, Philadelphia, PA. He trained in surgery at Strong Memorial Hospital, University of Rochester, NY and completed urology residency at Brigham and Women’s Hospital, Harvard Medical School, Boston, MA. He served a fellowship in Urologic Oncology at the National Cancer Institute of NIH in Bethesda, Maryland prior to joining the faculty at Washington University.

Susan L. Drexler is currently a consultant at Danforth Advisors, LLC and is serving as the Interim Chief Financial Officer for Syncromune.  Ms. Drexler has extensive experience as a chief financial officer, with over 25 years of experience working with several stages of  life science companies, ranging from startup to commercial stage.

Since January 2022, Ms. Drexler has served as a consultant at Danforth, a provider of strategic and operational finance and accounting for life science companies. Ms. Drexler previously served as interim chief financial officer of Aileron Therapeutics (now Rein Therapeutics) and Kiora Pharmaceuticals, Inc., both clinical-stage specialty pharmaceutical companies. Prior to Danforth Advisors, Ms. Drexler served as chief financial officer of Harmony Biosciences Holdings, Inc., a pharmaceutical company, from October 2019 through March 2021.  Ms. Drexler also served as acting chief financial officer and vice president, business development of Ocugen, Inc., a biotechnology company, from April 2018 through June 2019 and as senior director, strategy and business development.

Prior to Ocugen she served as vice president, business development and market intelligence at AmerisourceBergen Drug Corporation, a pharmaceutical sourcing and distribution services company, from August 2015 through November 2017. Ms. Drexler previously served as director, corporate finance of Shire plc from 2007 through 2015. Earlier in her career she held roles of increasing responsibility in finance consulting at Duff & Phelps, LLC and senior audit roles at PricewaterhouseCoopers LLP.  She received a B.S. in Accounting from Albright College, an MBA in Finance from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh, and is a Certified Public Accountant in the State of Pennsylvania.

Dr. Li brings 18 years of regulatory and drug development experience spanning the U.S. FDA, Pfizer, Biocytogen/Eucure and Belief Biomed. He has extensive experience spanning across all phases of drug product life cycle and special expertise regarding clinical development plan, clinical trial design, regulatory strategy to meet US FDA, China NMPA and Australia EC requirements, interpretation and implementation of FDA guidances, ICH guidelines and other regulatory policies. In addition, Dr. Li has working experience in applying FDA expedited programs and special designations such as orphan drug designation.

During his tenure at the FDA’s Center for Drug Evaluation and Research (CDER), Dr. Li conducted regulatory reviews of over 200 INDs, NDAs, and BLAs, providing critical insights into clinical trial design, expedited program applications, and regulatory approvals for oncology and immunotherapy products. In his industry roles, he successfully led multiple IND submissions in the U.S. and China, secured expedited program designations, and guided regulatory pathways for novel biologics, gene therapies, and oncology products. His leadership has helped transition multiple early-stage assets into clinical development and regulatory approval.

As former Chief Regulatory and Strategy Officer at Biocytogen/Eucure, Dr. Li has first-hand experience working with Syncromune’s licensed antibodies (CTLA-4, CD40, and OX40), providing a unique advantage in advancing the company’s immuno-oncology portfolio. Additionally, his fluency in Mandarin and deep understanding of international regulatory environments will strengthen Syncromune’s global partnerships.

Dr. Li completed his Ph.D. at the University of Minnesota Department of Pharmaceutics, and M.S. and B.S. degrees from the Beijing Medical University School of Pharmaceutical Sciences.

Dr. Mautino is a senior R&D executive and translational scientist with diverse experience in drug discovery and development, including strategic planning, program management, and intellectual property management. He brings 25+ years of experience in the fields of immuno-oncology, immunology, basic research, medicinal chemistry, bioassays, pharmacology, toxicology, safety pharmacology, clinical pharmacology, IND filings, regulatory guidelines, quality, pharmaceutical development, and drug substance and drug product manufacturing.

He has led multiple research projects related to design of vaccines, and research of combinations of therapeutic modalities in different cancer models including chemotherapy, radiation, vaccination, inhibition of metabolic, and other immune checkpoints.